Aura Biosciences announced the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AURA:
- Aura Biosciences price target lowered to $19 from $21 at JMP Securities
- Insider Trading: Aura Biosciences Stock (NASDAQ:AURA) Bought by Insiders to the Tune of $16M
- Aura Biosciences reports Q3 EPS (48c), consensus (52c)
- Aura Biosciences price target lowered to $20 from $23 at Scotiabank
- Aura Biosciences 11M share Spot Secondary priced at $9.00
